Fig. 7: Knockdown or inhibition of USP10 suppresses lung and ovarian cancer xenograft growth and sensitizes xenografts to cisplatin treatment in immune-deficient mice.

a–d Knockdown of USP10 inhibits H23, H1299, SKOV3, and ES-2 xenograft growth in immune-deficient mice. a, b The volumes of H23 and H1299 control implants or H23 and H1299 USP10 knockdown implants in SCID mice were measured every 2–3 days as described in the Methods. c, d The SKOV3 and ES-2 control or SKOV3 and ES-2 USP10 knockdown cells were injected into the nude mice as described in the Methods. The tumor volumes were measured weekly. e, f The SKOV3 and ES-2 control or SKOV3 and ES-2 USP10 knockdown xenografts were weighted (e) and the tumors’ images were taken as shown in f. For SKOV3, n = 6; for ES-2, n = 5. g–i Knockdown of USP10 sensitizes the H157 xenografts to cisplatin. H157-control and H157-USP10KD tumors were treated i.v. with either vehicle or cisplatin (at 2 mg/kg), starting on day 1 on a Q3dx5 schedule for a total dose of 10 mg/kg. Mice were euthanized 15 days post-implantation. Tumor volumes were shown in g. Photos of the tumors were shown in h. Tumor weight was quantified in bar graphs shown in i. j Inhibition of USP10 reduces H1299 tumor growth and sensitizes H1299 xenografts to cisplatin in nude mice. The growth curve of H1299 xenograft tumors treated with vehicle, cisplatin (3 mg/kg, intravenous (i.v.) injection), USP10 inhibitor P22077 (15 mg/kg, intraperitoneal (i.p.) injection) and cisplatin plus P22077 was shown. Tumor volumes were calculated as above; n = 5 per group. k Tumor images of H1299 xenografts. l Body weight of mice used in j was measured during the treatment. * p < 0.05, **p < 0.01, ***p < 0.001.